4.7 Article

Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 2020

Journal

EMERGING INFECTIOUS DISEASES
Volume 27, Issue 6, Pages 1598-1606

Publisher

CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2706.210568

Keywords

-

Funding

  1. World Health Organization's (WHO) Unity Studies, a global seroepidemiologic standardization initiative
  2. COVID-19 Solidarity Response Fund
  3. German Federal Ministry of Health COVID-19 Research and Development Fund
  4. African Development Bank Fund
  5. US National Institutes of Health [R01 AI135115]
  6. US Centers for Disease Control and Prevention [U01CK000490]
  7. European Civil Protection and Humanitarian Aid Operations
  8. US Office of Foreign Disaster Assistance
  9. UK Foreign, Commonwealth and Development Office
  10. German Federal Foreign Office
  11. Canada's Department of Foreign Affairs, Trade and Development

Ask authors/readers for more resources

A study conducted in Juba, South Sudan found that approximately 38.3% of the population had been infected with SARS-CoV-2, with unreported infections likely being much higher than reported cases. Additionally, differences in background reactivity were observed between Juba and Boston, Massachusetts, where the immunoassay was validated.
Relatively few coronavirus disease cases and deaths have been reported from sub-Saharan Africa, although the extent of its spread remains unclear. During August 10-September 11, 2020, we recruited 2,214 participants for a representative household-based cross-sectional serosurvey in Juba, South Sudan. We found 22.3% of participants had severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain IgG titers above prepandemic levels. After accounting for waning antibody levels, age, and sex, we estimated that 38.3% (95% credible interval 31.8%-46.5%) of the population had been infected with SARS-CoV-2. At this rate, for each PCR-confirmed SARS-CoV-2 infection reported by the Ministry of Health, 103 (95% credible interval 86-126) infections would have been unreported, meaning SARS-CoV-2 has likely spread extensively within Juba. We also found differences in background reactivity in Juba compared with Boston, Massachusetts, USA, where the immunoassay was validated. Our findings underscore the need to validate serologic tests in sub-Saharan Africa populations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available